Our research method

The work behind
the view.

A good company is only part of a good investment. We examine the business, the price and what could go wrong, then show the evidence behind the conclusion.

How the research is built

How a report takes shape.

A consistent process connects the source material to the investment case.

  1. 01

    Start with the record.

    Research begins with company filings and financial disclosures, with sources kept close to the conclusions.

  2. 02

    Examine the business.

    We examine business quality, financial resilience and the risks that could undermine the investment case.

  3. 03

    Test the investment case.

    Scenarios consider what could go right, what could go wrong and what the current price assumes.

  4. 04

    Check the work.

    Automated checks review consistency and supporting evidence before research enters the library.

Research is produced by AI agents and checked automatically. These checks do not replace your judgment or guarantee accuracy.

A business rating.
A view at a price.

The rating describes the business and its risks. The investment view also considers the price and downside case. That distinction matters: a strong business can still be a Hold.

The business and its risks

Each report explains the company’s strengths, weaknesses and the evidence behind its assessment.

The opportunity at a price

Valuation scenarios put potential returns in context and show where the investment case depends on assumptions.

What would change the view

Key risks and conditions give you something concrete to question as the company develops.

Where the method can be wrong.

Confidence should come with a clear account of uncertainty.

Research is a considered view of uncertain outcomes. Assumptions can fail, sources can be incomplete, and conclusions can be wrong.

A measured investment track record has not yet been published. Scenarios and ratings are not promises of returns. Check each report’s dates and stated limitations before relying on it.

The same research is available to every member. It does not account for your personal finances or investment objectives.

Different businesses.
Different questions.

Established companies, high-growth businesses and clinical-stage biotech need different kinds of analysis. Specialist growth and biotech research remains in beta, with its limitations stated in each report.

A view with a date.

Reports identify the information and price they reflect. Read those dates alongside the risks and assumptions; the investment case can change as new information emerges.